Clinical Trial Update: Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461) [Phase 1]

View source ↗

Summary

Phase 1 trial update on long-term immunogenicity of the HIV gp120-NefTat/AS01B vaccine (GSK SB732461) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections
• Infection Human Immunodeficiency Virus

Drugs mentioned

• HIV gp120-NefTat/AS01B vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2019-11-18